Dr. Giermasz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 Stockton Blvd Suite 202
Sacramento, CA 95817Phone+1 916-734-3461Fax+1 916-734-3591
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2008 - 2011
UPMC Medical EducationResidency, Internal Medicine, 2005 - 2008
Medical University of WarsawClass of 1998
Certifications & Licensure
CA State Medical License 2008 - 2026
PA State Medical License 2005 - 2008- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- 5 citationsPERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A...Miguel A. Escobar, James V. Luck, Yevhenii Averianov, Jonathan M. Ducore, Maria Fernanda Lopez Fernandez
Haemophilia. 2021-10-06 - 24 citationsHelper function of memory CD8+ T cells: Heterologous CD8 + T cells support the induction of therapeutic cancer immunityYutaro Nakamura, Payal Watchmaker, Julie Urban, Brian S. Sheridan, Adam Giermasz
Cancer Research. 2007-10-15 - 72 citationsEtranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia BAnnette von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore
Blood Advances. 2019-11-12
Abstracts/Posters
- Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patien...Adam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 YearAdam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia BAdam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
ASH 2020: Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults with Severe Hemophilia ADecember 18th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
